Lyell Immunopharma Advances CAR-T Candidate with Pivotal Head-to-Head Trial

Lyell Immunopharma has initiated its crucial Phase 3 clinical trial, named PiNACLE – H2H, for its next-generation CAR T-cell therapy candidate, LYL314. This study represents a bold strategic move for the biotechnology firm, as it will directly compare LYL314 against approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma.

The initiation of the PiNACLE – H2H study signals a direct competitive challenge from Lyell Immunopharma. The head-to-head trial design, pitting LYL314 against established CD19 CAR T-cell treatments, has a clear objective: to demonstrate either superior efficacy or an improved safety profile for second-line treatment of aggressive large B-cell lymphoma.

LYL314 is a novel, dual-targeting therapy designed to engage both CD19 and CD20 antigens. This next-generation... Read more...